Astellas installs president at OSI
This article was originally published in Scrip
Astellas has named Naoki Okamura as president of its wholly owned US subsidiary OSI Pharmaceuticals. Mr Okamura was formerly an executive in Astellas's licensing and alliances department. Around a month ago, the Japanese firm completed its $4 billion acquisition of OSI, whose CEO is Dr Colin Goddard. The move will give Astellas a greater presence in the oncology sector and the US market (scripintelligence.com, 17 May 2010).